1 week Ago By Defense World Staff
Geode Capital Management LLC reduced its position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK – Free Report) by 0.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC.
The firm owned 322,778 shares of the biotechnology company’s stock after selling 2,186 shares during the quarter. Geode Capital Management LLC owned about 2.20% of Anika Therapeutics worth $5,315,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in Anika Therapeutics by 431.
9% during the 4th quarter. JPMorgan Chase & Co. now owns 82,491 shares of the biotechnology company’s stock valued at $1,358,000 after purchasing an additional 66,982 shares during the last quarter.
Capital Management Corp VA boosted its position in shares of Anika Therapeutics by 12.1% during the fourth quarter. Capital Management Corp VA now owns 325,545 shares of the biotechnology company’s stock valued at $5,358,000 after buying an additional 35,195 shares during the last quarter.
Barclays PLC boosted its position in shares of Anika Therapeutics by 66.6% during the third quarter. Barclays PLC now owns 32,664 shares of the biotechnology company’s stock valued at $806,000 after buying an additional 13,054 shares during the last quarter.
Bank of New York Mellon Corp grew its holdings in Anika Therapeutics by 20.8% during the fourth quarter. Bank of New York Mellon Corp now owns 50,529 shares of the biotechnology company’s stock worth $832,000 after buying an additional 8,711 shares in the last quarter.
Finally, Jane Street Group LLC raised its position in Anika Therapeutics by 54.1% in the 3rd quarter. Jane Street Group LLC now owns 24,351 shares of the biotechnology company’s stock valued at $601,000 after buying an additional 8,550 shares during the last quarter.
Institutional investors own 91.53% of the company’s stock. Anika Therapeutics Price PerformanceShares of NASDAQ ANIK opened at $14.
43 on Friday. The stock has a market capitalization of $204.56 million, a P/E ratio of -2.
17 and a beta of 0.82. Anika Therapeutics, Inc.
has a one year low of $12.83 and a one year high of $29.12.
The firm’s 50 day simple moving average is $15.44 and its two-hundred day simple moving average is $17.23.
Anika Therapeutics (NASDAQ:ANIK – Get Free Report) last released its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.
01) by ($0.13). The business had revenue of $30.
60 million for the quarter, compared to the consensus estimate of $29.00 million. Anika Therapeutics had a negative net margin of 59.
40% and a negative return on equity of 2.22%. As a group, equities analysts expect that Anika Therapeutics, Inc.
will post -0.84 earnings per share for the current fiscal year. Analyst Upgrades and DowngradesA number of equities research analysts have recently commented on the company.
B. Riley started coverage on Anika Therapeutics in a research note on Thursday, April 17th. They set a “buy” rating and a $21.
00 target price on the stock. Barrington Research reduced their price objective on shares of Anika Therapeutics from $25.00 to $20.
00 and set an “outperform” rating for the company in a research note on Thursday, March 13th. Finally, StockNews.com upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th.
Get Our Latest Report on Anika TherapeuticsAnika Therapeutics Company Profile (Free Report)Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.Further ReadingFive stocks we like better than Anika Therapeutics3 Stocks to Consider Buying in OctoberMarkets Think Robinhood Earnings Could Send the Stock Up3 Warren Buffett Stocks to Buy NowChurchill Downs Stock: Could Tariff Fears Dampen Derby Gains?How is Compound Interest Calculated?AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround.
